FDA Removes Hold on Juno Therapeutics’ Cancer Trial

Less than a week after the FDA halted Juno Therapeutics’ Phase 2 cancer trial over three patient deaths, the agency has given the company the go-ahead to resume the trial.

The agency lifted its clinical hold on the company’s research after Juno pledged to alter its protocols. Now, the company will use only cyclophosphamide when preparing patients for treatment, rather than the fludarabine-cyclophosphamide combination that is believed to be the reason one patient died in May and two more in June.